Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide

Publisher： Karger

E-ISSN： 1423-0232|77|2|134-139

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.2, 2009-07, pp. : 134-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 274-281

Karger

Access to resources Recommend Favorite

Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer

By  

Oncology, Vol. 55, Iss. 6, 1998-10 ,pp. : 533-537

Karger

Access to resources Recommend Favorite

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3943-3951

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I/II Study of Paclitaxel and 5-Fluorouracil as Second-Line Therapy in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 305-308

Karger

Access to resources Recommend Favorite

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 185-191

Karger

Access to resources Recommend Favorite